Jay Harvey, DO
Epilepsy · Dallas, TXNPI 1972511517
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Jazz Pharmaceuticals Inc. accounts for 80.7% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $11,272, more than ten times the $224 reported in 2019. Among epilepsy clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $519.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$16K
- Azurity Pharmaceuticals, Inc.$2K
- Neuropace, Inc.$745
- Aquestive Therapeutics, Inc.$630
- UCB, Inc.$397
- SK Life Science, Inc.$193
- plus $243 from 5 others
Across 15 payments — averaging $17,317 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$130K
- UCB SA$91K
- Jazz Pharmaceuticals Inc.$31K
- SK Life Science, Inc.$8K
- Monteris Medical Corporation$1K
What the payments were for
- Consulting fees$4,92526%
- Speaking & faculty fees$11,11558%
- Travel & lodging$1,5728%
- Food & beverage$1,4177%
- Education$1931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 11 | $15,514 |
| Azurity Pharmaceuticals, Inc. | 1 | $1,500 |
| Neuropace, Inc. | 8 | $745 |
| Aquestive Therapeutics, Inc. | 1 | $630 |
| UCB, Inc. | 5 | $397 |
| SK Life Science, Inc. | 3 | $193 |
| Livanova USA, Inc. | 2 | $142 |
| AbbVie | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Greenwich Biosciences, Inc. | 1 | $13 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$15,224
- ZONISADE$1,500
- SYMPAZAN$630
- RNS Neurostimulator Kit$607
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$114
How this compares
$19,221 in reported general payments places this provider in the 90th percentile of 36 epilepsy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 74 | $544,476 |
| BriviactBrivaracetam | 78 | $212,008 |
| XcopriCenobamate | 62 | $120,211 |
| TopamaxTopiramate | 23 | $94,071 |
| VimpatLacosamide | 33 | $74,935 |
| FycompaPerampanel | 36 | $66,711 |
| OnfiClobazam | 23 | $66,540 |
| LamictalLamotrigine | 26 | $64,463 |
| AptiomEslicarbazepine Acetate | 18 | $45,487 |
| NayzilamMidazolam | 22 | $44,058 |
| Lamictal XrLamotrigine | 17 | $43,012 |
| Lacosamide | 121 | $30,129 |
| Topiramate ErTopiramate | 12 | $25,641 |
| Felbamate | 37 | $20,747 |
| TrileptalOxcarbazepine | 11 | $20,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Vimpat, Nayzilam | $397 | $331,000133 claims |
| SK Life Science, Inc.Xcopri | $193 | $120,21162 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $36 | $45,48718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 epilepsy providers in Texas.
Other epilepsy in Dallas
- Erin FiedlerDallas$9K
- Milena SampaioDallas$2K
- Irfan SheikhDallas$399
- Ryan HaysDallas$113
- Mohammad TabaDallas$88
- Karen KeoughAustin$474K
- Katherine LabinerAustin$163K
- Charles SzaboSan Antonio$15K
- Daniel GustkeyAustin$12K
- Linda LearySan Antonio$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.